A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

Clinical trial NCT05469178 · TERMINATED

Trial details

NCT number: NCT05469178
Sponsor: BerGenBio ASA
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2023-03-03
Primary completion: 2025-04-03
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.